Pan-Cancer (N=930) | HB-Cancer (N=1151) | Pan-disease (N=4409) | HB-disease (N=21002) | Control (N=5895) | Total (N=33387) | p value | |
---|---|---|---|---|---|---|---|
Gender | < 0.0011 | ||||||
   Female | 439 (47.2%) | 430 (37.4%) | 2043 (46.3%) | 11186 (53.3%) | 1681 (28.5%) | 15779 (47.3%) | |
   Male | 491 (52.8%) | 721 (62.6%) | 2366 (53.7%) | 9816 (46.7%) | 4214 (71.5%) | 17608 (52.7%) | |
Ethnicity | < 0.0011 | ||||||
   White | 519 (66.6%) | 549 (53.7%) | 2370 (57.6%) | 10396 (51.5%) | 3280 (57.7%) | 17114 (53.9%) | |
   South Asian | 79 (10.1%) | 230 (22.5%) | 874 (21.2%) | 5207 (25.8%) | 942 (16.6%) | 7332 (23.1%) | |
   Black | 98 (12.6%) | 121 (11.8%) | 408 (9.9%) | 2046 (10.1%) | 806 (14.2%) | 3479 (10.9%) | |
   Far/South-east Asian | 4 (0.5%) | 24 (2.3%) | 19 (0.5%) | 234 (1.2%) | 31 (0.5%) | 312 (1.0%) | |
   Arab/North African | 0 (0.0%) | 0 (0.0%) | 1 (0.0%) | 15 (0.1%) | 5 (0.1%) | 21 (0.1%) | |
   Asian (Other) | 17 (2.2%) | 46 (4.5%) | 178 (4.3%) | 970 (4.8%) | 234 (4.1%) | 1445 (4.5%) | |
   Mixed | 9 (1.2%) | 8 (0.8%) | 49 (1.2%) | 241 (1.2%) | 78 (1.4%) | 385 (1.2%) | |
   Other | 53 (6.8%) | 45 (4.4%) | 217 (5.3%) | 1065 (5.3%) | 306 (5.4%) | 1686 (5.3%) | |
Diagnosis age (years) | < 0.0012 | ||||||
   Mean (SD) | 66.91 (12.72) | 65.24 (13.22) | 52.90 (18.51) | 53.64 (17.67) | 54.77 (17.59) | 54.51 (17.77) | |
   Median | 67.21 | 66.06 | 51.28 | 52.42 | 54.09 | 53.62 | |
   Q1,Q3 | 58.88, 76.07 | 56.79, 75.15 | 38.36, 67.20 | 39.90, 66.40 | 41.02, 68.00 | 40.66, 67.85 | |
Diagnosis age group | < 0.0011 | ||||||
   18-40 | 27 (2.9%) | 54 (4.7%) | 1318 (29.9%) | 5663 (27.0%) | 1470 (24.9%) | 8532 (25.6%) | |
   41-50 | 66 (7.1%) | 100 (8.7%) | 862 (19.6%) | 4149 (19.8%) | 1097 (18.6%) | 6274 (18.8%) | |
   51-60 | 189 (20.3%) | 266 (23.1%) | 773 (17.5%) | 4186 (19.9%) | 1163 (19.7%) | 6577 (19.7%) | |
   61-70 | 290 (31.2%) | 325 (28.2%) | 574 (13.0%) | 3022 (14.4%) | 961 (16.3%) | 5172 (15.5%) | |
   71-80 | 234 (25.2%) | 273 (23.7%) | 519 (11.8%) | 2311 (11.0%) | 733 (12.4%) | 4070 (12.2%) | |
   >80 | 124 (13.3%) | 133 (11.6%) | 363 (8.2%) | 1671 (8.0%) | 471 (8.0%) | 2762 (8.3%) | |
Mortality | < 0.0011 | ||||||
   Deceased | 754 (81.1%) | 795 (69.1%) | 840 (19.1%) | 3634 (17.3%) | 614 (10.4%) | 6637 (19.9%) | |
   Survived | 176 (18.9%) | 356 (30.9%) | 3569 (80.9%) | 17368 (82.7%) | 5281 (89.6%) | 26750 (80.1%) | |
Survival (months) | < 0.0012 | ||||||
   Mean (SD) | 15.88 (24.91) | 22.37 (29.54) | 49.69 (64.39) | 58.03 (77.33) | 57.50 (71.17) | 54.43 (73.08) | |
   Median | 8.05 | 12.47 | 28.93 | 34.87 | 36.57 | 32.20 | |
   Q1,Q3 | 2.58, 18.18 | 3.52, 29.40 | 9.60, 66.17 | 12.50, 73.46 | 14.57, 71.95 | 11.07, 69.57 |
Pan-Cancer (N=930) | Control (N=5895) | Total (N=6825) | p value | |
---|---|---|---|---|
Gender | < 0.0011 | |||
   Female | 439 (47.2%) | 1681 (28.5%) | 2120 (31.1%) | |
   Male | 491 (52.8%) | 4214 (71.5%) | 4705 (68.9%) | |
Ethnicity | < 0.0011 | |||
   White | 519 (66.6%) | 3280 (57.7%) | 3799 (58.8%) | |
   South Asian | 79 (10.1%) | 942 (16.6%) | 1021 (15.8%) | |
   Black | 98 (12.6%) | 806 (14.2%) | 904 (14.0%) | |
   Far/South-east Asian | 4 (0.5%) | 31 (0.5%) | 35 (0.5%) | |
   Arab/North African | 0 (0.0%) | 5 (0.1%) | 5 (0.1%) | |
   Asian (Other) | 17 (2.2%) | 234 (4.1%) | 251 (3.9%) | |
   Mixed | 9 (1.2%) | 78 (1.4%) | 87 (1.3%) | |
   Other | 53 (6.8%) | 306 (5.4%) | 359 (5.6%) | |
Diagnosis age (years) | < 0.0012 | |||
   Mean (SD) | 66.91 (12.72) | 54.77 (17.59) | 56.42 (17.51) | |
   Median | 67.21 | 54.09 | 56.66 | |
   Q1,Q3 | 58.88, 76.07 | 41.02, 68.00 | 42.91, 69.62 | |
Diagnosis age group | < 0.0011 | |||
   18-40 | 27 (2.9%) | 1470 (24.9%) | 1497 (21.9%) | |
   41-50 | 66 (7.1%) | 1097 (18.6%) | 1163 (17.0%) | |
   51-60 | 189 (20.3%) | 1163 (19.7%) | 1352 (19.8%) | |
   61-70 | 290 (31.2%) | 961 (16.3%) | 1251 (18.3%) | |
   71-80 | 234 (25.2%) | 733 (12.4%) | 967 (14.2%) | |
   >80 | 124 (13.3%) | 471 (8.0%) | 595 (8.7%) | |
Mortality | < 0.0011 | |||
   Deceased | 754 (81.1%) | 614 (10.4%) | 1368 (20.0%) | |
   Survived | 176 (18.9%) | 5281 (89.6%) | 5457 (80.0%) | |
Survival (months) | < 0.0012 | |||
   Mean (SD) | 15.88 (24.91) | 57.50 (71.17) | 51.83 (68.29) | |
   Median | 8.05 | 36.57 | 30.80 | |
   Q1,Q3 | 2.58, 18.18 | 14.57, 71.95 | 10.43, 66.67 |
Pan-Cancer (N=930) | Control (N=5895) | Total (N=6825) | p value | |
---|---|---|---|---|
Comorbidity | < 0.0011 | |||
   Mean (SD) | 3.14 (2.25) | 1.92 (1.87) | 2.09 (1.97) | |
   Median | 3.00 | 1.00 | 2.00 | |
   Q1,Q3 | 1.00, 5.00 | 0.00, 3.00 | 0.00, 3.00 | |
Diabetes | 353 (38.0%) | 1010 (17.1%) | 1363 (20.0%) | < 0.0012 |
Hypertension | 490 (52.7%) | 2545 (43.2%) | 3035 (44.5%) | < 0.0012 |
Cholesterol | 423 (45.5%) | 2226 (37.8%) | 2649 (38.8%) | < 0.0012 |
Asthma | 104 (11.2%) | 874 (14.8%) | 978 (14.3%) | 0.0032 |
COPD | 72 (7.7%) | 306 (5.2%) | 378 (5.5%) | 0.0022 |
TB | 8 (0.9%) | 67 (1.1%) | 75 (1.1%) | 0.4522 |
Kidney | 160 (17.2%) | 821 (13.9%) | 981 (14.4%) | 0.0082 |
Cardiovascular | 262 (28.2%) | 1362 (23.1%) | 1624 (23.8%) | < 0.0012 |
Upper GI | 292 (31.4%) | 1287 (21.8%) | 1579 (23.1%) | < 0.0012 |
Lower GI | 109 (11.7%) | 682 (11.6%) | 791 (11.6%) | 0.8932 |
F/H: Cancer | 81 (8.7%) | 1141 (19.4%) | 1222 (17.9%) | < 0.0012 |
F/H: Digestive | 43 (4.6%) | 120 (2.0%) | 163 (2.4%) | < 0.0012 |
F/H: Diabetes | 146 (15.7%) | 1484 (25.2%) | 1630 (23.9%) | < 0.0012 |
Pan-Cancer (N=930) | Control (N=5895) | Total (N=6825) | p value | |
---|---|---|---|---|
Smoker | < 0.0011 | |||
   Not available | 289 (31.1%) | 481 (8.2%) | 770 (11.3%) | |
   Never | 238 (25.6%) | 2278 (38.6%) | 2516 (36.9%) | |
   Past | 236 (25.4%) | 1767 (30.0%) | 2003 (29.3%) | |
   Current | 167 (18.0%) | 1369 (23.2%) | 1536 (22.5%) | |
Drinker | < 0.0011 | |||
   Not available | 423 (45.5%) | 1228 (20.8%) | 1651 (24.2%) | |
   Never | 118 (12.7%) | 1340 (22.7%) | 1458 (21.4%) | |
   Past | 48 (5.2%) | 291 (4.9%) | 339 (5.0%) | |
   Current | 341 (36.7%) | 3036 (51.5%) | 3377 (49.5%) | |
Substance user | < 0.0011 | |||
   Not available | 627 (67.4%) | 2739 (46.5%) | 3366 (49.3%) | |
   Never | 115 (12.4%) | 2117 (35.9%) | 2232 (32.7%) | |
   Past | 4 (0.4%) | 37 (0.6%) | 41 (0.6%) | |
   Current | 184 (19.8%) | 1002 (17.0%) | 1186 (17.4%) | |
Obese | < 0.0011 | |||
   Not available | 256 (27.5%) | 540 (9.2%) | 796 (11.7%) | |
   Never | 190 (20.4%) | 1269 (21.5%) | 1459 (21.4%) | |
   Past | 337 (36.2%) | 2539 (43.1%) | 2876 (42.1%) | |
   Current | 147 (15.8%) | 1547 (26.2%) | 1694 (24.8%) |
Pan-Cancer (N=540) | Control (N=5074) | Total (N=5614) | p value | |
---|---|---|---|---|
Gender | < 0.0011 | |||
   Female | 265 (49.1%) | 1457 (28.7%) | 1722 (30.7%) | |
   Male | 275 (50.9%) | 3617 (71.3%) | 3892 (69.3%) | |
Ethnicity | 0.0531 | |||
   White | 324 (60.3%) | 2788 (55.5%) | 3112 (56.0%) | |
   South Asian | 71 (13.2%) | 898 (17.9%) | 969 (17.4%) | |
   Black | 87 (16.2%) | 755 (15.0%) | 842 (15.1%) | |
   Far/South-east Asian | 2 (0.4%) | 29 (0.6%) | 31 (0.6%) | |
   Arab/North African | 0 (0.0%) | 5 (0.1%) | 5 (0.1%) | |
   Asian (Other) | 15 (2.8%) | 219 (4.4%) | 234 (4.2%) | |
   Mixed | 5 (0.9%) | 71 (1.4%) | 76 (1.4%) | |
   Other | 33 (6.1%) | 260 (5.2%) | 293 (5.3%) | |
Diagnosis age (years) | < 0.0012 | |||
   Mean (SD) | 67.15 (13.68) | 53.84 (17.18) | 55.12 (17.33) | |
   Median | 67.01 | 53.14 | 54.83 | |
   Q1,Q3 | 57.95, 77.72 | 40.29, 66.68 | 41.59, 68.12 | |
Diagnosis age group | < 0.0011 | |||
   18-40 | 19 (3.5%) | 1326 (26.1%) | 1345 (24.0%) | |
   41-50 | 41 (7.6%) | 991 (19.5%) | 1032 (18.4%) | |
   51-60 | 115 (21.3%) | 1010 (19.9%) | 1125 (20.0%) | |
   61-70 | 148 (27.4%) | 820 (16.2%) | 968 (17.2%) | |
   71-80 | 124 (23.0%) | 581 (11.5%) | 705 (12.6%) | |
   >80 | 93 (17.2%) | 346 (6.8%) | 439 (7.8%) | |
Mortality | < 0.0011 | |||
   Deceased | 437 (80.9%) | 483 (9.5%) | 920 (16.4%) | |
   Survived | 103 (19.1%) | 4591 (90.5%) | 4694 (83.6%) | |
Survival (months) | < 0.0012 | |||
   Mean (SD) | 17.83 (29.58) | 64.21 (73.97) | 59.75 (72.22) | |
   Median | 7.93 | 42.40 | 38.00 | |
   Q1,Q3 | 2.58, 18.38 | 19.81, 78.11 | 16.27, 74.17 |
Pan-Cancer (N=540) | Control (N=5074) | Total (N=5614) | p value | |
---|---|---|---|---|
Comorbidity | < 0.0011 | |||
   Mean (SD) | 4.09 (2.15) | 1.99 (1.92) | 2.19 (2.04) | |
   Median | 4.00 | 2.00 | 2.00 | |
   Q1,Q3 | 2.00, 5.00 | 0.00, 3.00 | 0.00, 4.00 | |
Diabetes | 250 (46.3%) | 884 (17.4%) | 1134 (20.2%) | < 0.0012 |
Hypertension | 353 (65.4%) | 2183 (43.0%) | 2536 (45.2%) | < 0.0012 |
Cholesterol | 361 (66.9%) | 2065 (40.7%) | 2426 (43.2%) | < 0.0012 |
Asthma | 78 (14.4%) | 783 (15.4%) | 861 (15.3%) | 0.5452 |
COPD | 52 (9.6%) | 237 (4.7%) | 289 (5.1%) | < 0.0012 |
TB | 8 (1.5%) | 66 (1.3%) | 74 (1.3%) | 0.7262 |
Kidney | 133 (24.6%) | 679 (13.4%) | 812 (14.5%) | < 0.0012 |
Cardiovascular | 192 (35.6%) | 1131 (22.3%) | 1323 (23.6%) | < 0.0012 |
Upper GI | 248 (45.9%) | 1266 (25.0%) | 1514 (27.0%) | < 0.0012 |
Lower GI | 98 (18.1%) | 653 (12.9%) | 751 (13.4%) | < 0.0012 |
F/H: Cancer | 81 (15.0%) | 1141 (22.5%) | 1222 (21.8%) | < 0.0012 |
F/H: Digestive | 29 (5.4%) | 116 (2.3%) | 145 (2.6%) | < 0.0012 |
F/H: Diabetes | 146 (27.0%) | 1482 (29.2%) | 1628 (29.0%) | 0.2912 |
Pan-Cancer (N=540) | Control (N=5074) | Total (N=5614) | p value | |
---|---|---|---|---|
Smoker | 0.0161 | |||
   Not available | 5 (0.9%) | 16 (0.3%) | 21 (0.4%) | |
   Never | 201 (37.2%) | 2130 (42.0%) | 2331 (41.5%) | |
   Past | 203 (37.6%) | 1685 (33.2%) | 1888 (33.6%) | |
   Current | 131 (24.3%) | 1243 (24.5%) | 1374 (24.5%) | |
Drinker | < 0.0011 | |||
   Not available | 96 (17.8%) | 674 (13.3%) | 770 (13.7%) | |
   Never | 86 (15.9%) | 1204 (23.7%) | 1290 (23.0%) | |
   Past | 47 (8.7%) | 288 (5.7%) | 335 (6.0%) | |
   Current | 311 (57.6%) | 2908 (57.3%) | 3219 (57.3%) | |
Substance user | < 0.0011 | |||
   Not available | 331 (61.3%) | 2237 (44.1%) | 2568 (45.7%) | |
   Never | 72 (13.3%) | 1965 (38.7%) | 2037 (36.3%) | |
   Past | 4 (0.7%) | 33 (0.7%) | 37 (0.7%) | |
   Current | 133 (24.6%) | 839 (16.5%) | 972 (17.3%) | |
Obese | 0.0171 | |||
   Not available | 7 (1.3%) | 101 (2.0%) | 108 (1.9%) | |
   Never | 117 (21.7%) | 1174 (23.1%) | 1291 (23.0%) | |
   Past | 292 (54.1%) | 2400 (47.3%) | 2692 (48.0%) | |
   Current | 124 (23.0%) | 1399 (27.6%) | 1523 (27.1%) |